1202186-71-7

Usage

Classification

Broad-spectrum antibiotic This term indicates that the compound is effective against a wide range of microorganisms, including both Gram-negative and Gram-positive bacteria, as well as some anaerobic bacteria.

Mechanism of action

Inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit This explains how the compound works to stop the growth of bacteria by interfering with their ability to produce proteins, which are essential for their survival and reproduction.

Common uses

Treatment of serious infections such as typhoid fever, bacterial meningitis, and rickettsial infections This list provides examples of the types of infections that the antibiotic is typically used to treat, which are often severe and life-threatening.

Upstream product

• 1027345-21-6 (4'-chloro-4,4-dimethyl-3,4,5,6-tetrahydro-[1,1'-biphenyl]-2-yl)methanol 
• 4255-62-3 4,4-dimethylcyclohexane-1-one 
• 1053265-66-9 2-bromo-5,5'-bis-methylcyclohex-1-enylcarbaldehyde 
• 1679-18-1 4-Chlorophenylboronic acid 
• 64230-02-0 (E)-2-(hydroxymethylene)-4,4-dimethylcyclohexan-1-one 
• 873-77-8 (4-chlorphenyl)magnesium bromide 
• 105854-65-7 2-chloro-5,5-dimethylcyclohex-1-enecarbaldehyde 
• 1202186-79-5 1-(4-chlorophenyl)-2-(diethoxymethyl)-4,4-dimethylcyclohexanol 
• 1202186-75-1 (2E)-1-(4-chlorophenyl)-4,4-dimethyl-2-(((triisopropylsilyl)oxy)methylene)cyclohexanol 

Downstream Products

• 1065604-70-7 ethyl 4-(4-((4'-chloro-4,4-dimethyl-3,4,5,6-tetrahydro-[1,1'-biphenyl]-2-yl)methyl)piperazin-1-yl) benzoate 
• 1274804-96-4 1-[2-(4-chloro-phenyl)-5.5-dimethyl-cyclohex-1-enylmethyl]-piperidin-4-one 
• 1274802-46-8 N-{7-[2-(4-chlorobiphenyl)-5,5-dimethylcyclohex-1-enylmethyl]-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl}-4-((R)-3-morpholin-4-yl-1-phenylsulfanylmethyl-propylamino)-3-trifluoromethanesulfonylbenzenesulfonamide 
• 1027345-21-6 (4'-chloro-4,4-dimethyl-3,4,5,6-tetrahydro-[1,1'-biphenyl]-2-yl)methanol 
• 1027345-22-7 6-(bromomethyl)-4'-chloro-4,4-dimethyl-2,3,4,5-tetrahydro-1,1'-biphenyl 
• 1044598-91-5 4-(4-((4'-chloro-4,4-dimethyl-3,4,5,6-tetrahydro-[1,1'-biphenyl]-2-yl)methyl)piperazin-1-yl)benzoic acid 

Relevant academic research and scientific papers

CONDENSED HETEROCYCLES AS BCL-2 INHIBITORS

The disclosure includes compounds of Formula (A) wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, and R11, h, j, m, n, k, v, s, g, V, W, L, Z1 Q1, Q2, Q3, Q4, Q5, Q6, and Q7, are defined herein. Also disclosed is a method for treating a neoplastic disease, an autoimmune disease, or a neorodegenerative disease with these compounds.

HOT MELT EXTRUDED SOLID DISPERSIONS CONTAINING A BCL2 INHIBITOR

A pro-apoptotic solid dispersion comprises, a Bcl -2 family protein inhibitory compound of Formula A as defined herein, dispersed in a solid matrix that comprises (a) a pharmaceutically acceptable water-soluble polymeric carrier, and (b) a pharmaceutically acceptable surfactant. A process for preparing such a solid dispersion comprises subjecting to elevated temperature the compound of Formula A, the water-soluble polymeric carrier, and the surfactant to provide an extrudable semi-solid mixture; extruding the semi-solid mixture; and cooling the resulting extrudate to provide a solid matrix comprising the polymeric carrier, and the surfactant and having the compound dispersed in essentially non-crystalline form therein. The solid dispersion is suitable for oral administration to a subject in need thereof for treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl -2 family proteins, for example cancer or an immune or autoimmune disease.

Solid dispersions containing an apoptosis-inducing agent

A pro-apoptotic solid dispersion comprises, in essentially non-crystalline form, a Bcl-2 family protein inhibitory compound of Formula I as defined herein, dispersed in a solid matrix that comprises (a) a pharmaceutically acceptable water-soluble polymeric carrier and (b) a pharmaceutically acceptable surfactant. A process for preparing such a solid dispersion comprises dissolving the compound, the polymeric carrier and the surfactant in a suitable solvent, and removing the solvent to provide a solid matrix comprising the polymeric carrier and the surfactant and having the compound dispersed in essentially non-crystalline form therein. The solid dispersion is suitable for oral administration to a subject in need thereof for treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer.

ACYLSULFONAMIDE DERIVATIVES FOR TREATING SENESCENCE-ASSOCIATED DISEASES AND DISORDERS

Compounds represented by Formula (I) and (II) and salts thereof are described herein. The compounds or salts of Formula (I) and (II) may be used to treat senescence-associated diseases and disorders.

SULFONAMIDES AS INHIBITORS OF BCL-2 FAMILY PROTEINS FOR THE TREATMENT OF CANCER

The present invention includes novel compound and methods of treating a disease or disorder by antagonizing Bcl-2 family proteins, particularly compounds of Formula (I) or pharmaceutically acceptable salt thereof, as well as methods of treating a disease,

Processes To Make Apoptosis Promoters

Processes to make compounds, including N-acylsulfonamide apoptosis promoters are disclosed.